cd38 inhibitor and 5-amino-1mq synergy nad+ as a Regulator of Cellular NAD: A Novel Potential Pharmacological Target for Metabolic Conditions Biological Functions and Therapeutic Potential
Biological Functions and Therapeutic Potential of NAD+ Metabolism in Gynecological Cancers SLC25A51 decouples the mitochondrial NAD+ NADH ratio to control proliferation of AML cells: Cell Metabolism Targeting CD38 dependent NAD+ metabolism to mitigate multiple organ fibrosis ScienceDirect Targeting CD38 in Neoplasms and Non Cancer Diseases
Pay in 4 interest-free payments of $6.13 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 2 - Aug 7



